Yuhan Corporation is now selling biosimilar from Samsung Bioepis
입력 2017-10-12 09:37 수정 2017-10-12 09:37
바이오스펙테이터 Seunghyun Chon 기자
Yuhan Corporation takes full charge of domestic sales of biosmilar developed by Samsung Bioepis.
On October 11, Yuhan announced that they have signed exclusive sales contracts for two types of biosimilars in Korea with Samsung Bioepis. Brenzys and Renflexis, biosimilars of Remicade and Enbrel, are products sold by Yuhan now.
Both Brenzys and Renflexis are autoimmune disease agents that inhibit the expression of TNF-a, which are used in Crohn’s disease, rheumatoid arthritis.
Originally, MSD in Korea was responsible for sales of biosimilar products of Samsung Bioepis, but the sales company is now changed due to sluggish sales. Samsung Bioepis does not have a separate marketing and sales department, but only has research and development department of biosimilars.
Through this contract, Yuhan has entered into domestic TNF-alpha inhibitor antibody drug market, a 150 billion-scale market annually.
One of Yuhan officials said, “Our long, experienced marketing skills in Digestive and Rheumatic field medicines will create synergies in the future of the biopharmaceuticals pipeline of Samsung Bioepis”.
Samsung official said, “We have made constant efforts to increase accessibility of the biosimilar products to patients, and decided Yuhan as an optimal partner, which has a lot of interests in the growing domestic biopharmaceutical market”.